D.E. Shaw & Co
DFTX

D.E. Shaw & Co’s Definium Therapeutics DFTX Stock Holding History

D.E. Shaw & Co’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.14M Sell
271,717
-22,005
-7% -$373K ﹤0.01% 2147
2025
Q4 		$3.93M Buy
293,722
+77,388
+36% +$958K ﹤0.01% 2507
2025
Q3 		$2.55M Buy
216,334
+157,570
+268% +$1.47M ﹤0.01% 2795
2025
Q2 		$381K Sell
58,764
-4,485
-7% -$29.5K ﹤0.01% 3759
2025
Q1 		$370K Buy
+63,249
New +$453K ﹤0.01% 3661
2024
Q2 		– Sell
-183,029
Closed -$1.72M – 4701
2024
Q1 		$1.72M Buy
+183,029
New +$1.04M ﹤0.01% 2740
2022
Q1 		– Sell
-11,147
Closed -$231K – 5796
2021
Q4 		$231K Sell
11,147
-221
-2% -$7.05K ﹤0.01% 4810
2021
Q3 		$397K Buy
11,368
+2,514
+28% +$109K ﹤0.01% 4215
2021
Q2 		$458K Buy
+8,854
New +$465K ﹤0.01% 4078

Other funds holding DFTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

D.E. Shaw & Co's DFTX Position: Q1 2026 in Review

D.E. Shaw & Co reduced its Definium Therapeutics (DFTX) stake by 7.5% in Q1 2026, selling an estimated $373K and leaving 271,717 shares worth $5.14M. The position accounts for ﹤0.01% of the portfolio, ranked #2147.

D.E. Shaw & Co first reported a position in DFTX in Q2 2021 and has held it in 9 quarters since. 247 funds tracked by Wall St. Rank hold DFTX as of Q1 2026.

  • D.E. Shaw & Co held 271,717 shares of Definium Therapeutics worth $5.14M as of Q1 2026.
  • D.E. Shaw & Co sold 22,005 Definium Therapeutics shares in Q1 2026, an estimated $373K.
  • Definium Therapeutics made up ﹤0.01% of D.E. Shaw & Co's portfolio in Q1 2026, its #2147 holding.
  • D.E. Shaw & Co first reported a position in Definium Therapeutics in Q2 2021 and has held it in 9 quarters since.
  • 247 funds tracked by Wall St. Rank held Definium Therapeutics as of Q1 2026.

Based on D.E. Shaw & Co's 13F filing for Q1 2026, filed 15 May 2026.